The greatest risk factor for the development of cervical and other cancers that have been linked to the human papillomavirus (HPV) family is the persistence of the virus. To persist for the decades required to develop HPV-related cancers, the virus must escape host immunity. HPV is a simple DNA virus that has evolved to escape immune attack by a combination of stealth and interference. This review focuses on the mechanisms by which HPV can evade recognition by the host immune system.
INTRODUCTION
The human papillomavirus (HPV) is a family of sexually transmitted, double-stranded DNA viruses with over 100 different genotypes identified till date. It is associated with many different types of cancers including cervical, vaginal, head and neck, penile and anal cancer. With approximately 450,000 newly diagnosed cases each year and a 50% mortality rate [1, 2] , cervical cancer is the second most common cause of cancer-related death in women worldwide and it is almost always associated with HPV. In the United States, an estimated 75% of the sexually active general population ages 15 to 49 years acquires at least one genital HPV type during their lifetime [3] . Most individuals remain asymptomatic after acquiring the infection, and only a small percentage will develop clinically or histologically recognizable lesions.
HPV genotypes are divided into the low risk and high risk categories based on the spectrum of lesions they induce. The low-risk types induce only benign genital warts and include HPV 6 and 11. The high-risk group containing HPV 16, 18, 31, 33, 45 and 56 is associated with the development of anogenital cancers and can be detected in 99% of cervical cancers [4] , with HPV16 found in about 50% of cases [5] . Infection by the high-risk types is not confined to the anogenital area, since 18.3% of cancers of the oropharynx [6] contain DNA from these types.
Classification of the cellular atypia seen in HPV lesions varies from relatively benign lesions to invasive malignant neoplasms. At one end of the spectrum of HPV disease are anogenital warts and cervical intraepithelial neoplasia (CIN)/anal intraepithelial neoplasia (AIN) grade 1, also known as mild dysplasia. The CIN or AIN and mild dysplasia are combined into one single category known as "low grade squamous intraepithelial lesion" (LSIL). At the other end, there are CIN/AIN grades 2 and 3, also known as moderate and severe dysplasia respectively, and are *Address correspondence to this author at the Norris Comprehensive Cancer Center, ZNI 245, University of Southern California, 1501 San Pablo Street, Los Angeles, CA 90033, USA; Tel: (323) 442-3870; Fax: (323) 442-4433; E-mail: mkast@usc.edu categorized as "high grade squamous intraepithelial lesion" (HSIL). LSILs exhibit only slightly altered patterns of differentiation and are frequently cleared by the immune system in less than a year [7, 8] . However, some of these lesions do not spontaneously regress and can persist for periods as long as several decades. Although there are additional risk factors for the development of anogenital cancers such as immune-suppression [9] , co-infection with human immunodeficiency virus [10] , and cigarette smoking [11] , the persistence of high-risk HPV is the greatest risk factor for the development of anogenital malignancies [12] . To persist, HPV must escape the host immune system and this review will focus on mechanisms of immune escape by HPV. In this context, it is important to first discuss the life cycle and pathogenesis of HPV infections.
HPV LIFE CYCLE AND PATHOGENESIS
HPV are non-lytic, non-enveloped, icosahedral-shaped viruses that replicate their genomes in the nuclei of host cells using host cellular machinery. Their 7.9-kb circular, double-stranded DNA genome has a simple organization and can be separated into two coding regions and a non-coding regulatory region. The coding regions are denoted E and L for "early" proteins and "late" proteins, and encode on average 8 major open reading frames that are expressed from polycistronic mRNAs transcribed from a single DNA strand (reviewed in [13] ). The six E proteins are responsible for viral DNA replication, transcription and cellular transformation [12] . They fulfill regulatory functions vital for the production of viral progeny while the two L proteins are the capsid proteins responsible for virion assembly [14] and DNA packaging [15] . The functions of HPV genes have been discussed in detail elsewhere [16] [17] [18] and information directly relevant to immune escape mechanisms is discussed below.
Infection by papillomaviruses is unique in that it requires the availability of epidermal or mucosal epithelial cells that are capable of proliferation and their productive life cycle is coupled to the cellular differentiation cycle of host infected cells. Initial infection by HPV occurs in basal cells, a single layer of undifferentiated proliferating cells that are normally protected by non-dividing differentiated cells. Access to basal cells occurs through micro-abrasions caused by various forms of physical trauma. The receptor that mediates HPV entry into host cells is not known. Although HPV virions have been shown to bind heparin, a ubiquitous polysaccharide that may provide the initial attachment [19] and heparan sulfate has been shown to be required on the cell surface for HPV infection [20] , the receptor for HPV entry into basal cells has not been functionally identified. Thus, the precise steps of the entry process are yet to be elucidated and additional work is required to understand the mechanism by which HPV virions infect host basal epithelial cells.
HPV infection of basal cells leads to the activation of a cascade of viral gene expression that results in the replication of the viral genome. However, the expression of viral genes is largely suppressed and there is limited expression of specific early viral genes. The first viral genes to be expressed are the replication factors E1 and E2 which form a complex that bind to the origin of replication and act to recruit cellular polymerases and accessory proteins that mediate DNA replication [21] [22] [23] . Three HPV proteins (E5, E6 and E7) posses proliferation-stimulating activity. E5 stimulates cell growth by forming complexes with the epidermal-growth-factor receptor (EGFR), the plateletderived growth-factor-β receptor and the colony-stimulating factor-1 receptor [24] . It has also been shown to prevent apoptosis following DNA damage [25] . E6 and E7 are independently able to immortalize human cell types in tissue culture, but the efficiency is increased when they are expressed simultaneously [26, 27] . Together, expression of these viral proteins results in blockage of exit from the cell cycle and enhanced proliferation of infected cells containing hundreds of copies of the HPV genome per cell.
As infected cells divide, viral genomes are partitioned into the daughter cells. One daughter cell migrates to the suprabasal layers and undergoes differentiation, while the other continues to divide and is the reservoir for continuous viral replication. In uninfected cells, differentiation would lead to exit from the cell cycle, but infected cells remain in active cell cycle due to the action of E7 [28] and continue to replicate the viral genome. The functions of E4 and E5 in the replication process are not well understood, though they both have been proposed to be involved in the regulation of late viral functions [29] . Following entry into the suprabasal layers, "late" viral gene expression is initiated and the structural proteins (L1 and L2) are expressed. The L1 and L2 proteins spontaneously self-assemble into icosahedral capsids [30, 31] that contain the viral genome and mature virus particles are released from the uppermost layers of the epithelium when the differentiated cells are sloughed off at the end of their lifespan.
During the initial phase of infection, HPV is present as an episome, but in the majority of cancers, HPV has integrated into the host genome [32] . Integration results in the inactivation of the E2 open reading frame and a loss of its repressor function for E6 and E7 transcription, which allows for an accumulation of genetic changes [13] . While the molecular pathogenesis of cancer caused by the high-risk HPV types is not fully understood and although they are self-sufficient to induce carcinogenesis, the infection itself is not able to induce the malignant transformation of infected cells. The development of cervical cancer and the invasive phenotype requires more changes that are reviewed in detail elsewhere [18] .
MECHANISMS OF IMMUNE-EVASION
Though a large fraction of the sexually active population has been infected with HPV [3] , progression from infection to cancer is a very rare event that almost always involves accidental integration of the HPV genome into the DNA of the host cell [12] . This integration is a terminal event for the life cycle of the virus. Thus, it is important to distinguish between the mechanisms used by the virus and those used by tumor cells to evade the immune attack. Furthermore, viral oncogenesis and tumor progression are more likely to be rare by-products of the HPV life cycle, which has coevolved with its host such that it may not give the immune system a chance to eliminate virally infected cells. This review will focus on mechanisms adopted by HPV to avoid detection by the host immune system. Many viruses have evolved means to modulate host immune responses, presumably to allow for replication in a hostile, antiviral environment. Since none of the HPV genes have regulation of the immune system as their primary function, how does HPV escape detection by the host immune system?
Low Profile
HPV has enormous diversity with exquisite speciesspecificity and tissue-tropism. The reasons for this restriction of viral propagation are unknown. However, the replication of viral DNA in undifferentiated cells and subsequent particle formation in external differentiated epithelial cells reduces exposure to the host immune system. The failure of the immune system to recognize incoming or progeny virus may also be explained by the fact that the life cycle of HPV is non-lytic and therefore does not elicit any pro-inflammatory signals that activate the dendritic cells (DC) and induce migration into the local environment. The essential signals required for initiation of immune responses in squamous epithelia are absent [33] . The non-lytic nature of HPV infection limits the production of antigens that are processed and presented to the adaptive immune system. In addition, the virus encodes only non-secreted proteins. The majority of these, the E proteins, are expressed at low levels and primarily in the nucleus of infected cells [34] [35] [36] . Together with a lack of pro-inflammatory signals, this may be insufficient to activate the host immune response. Furthermore, the production of the highly immunogenic capsid proteins [37, 38] is limited to the terminally differentiated outer layer, which is shed from the epithelium. Since there is no blood-borne phase of the HPV life cycle and only minimal amounts of replicating virus are exposed to the immune system, the virus is essentially invisible to the host. Thus, the first strategy that HPV has evolved to avoid detection is to maintain a very low profile.
Preferred Codon Usage
The genetic code contains significant redundancy and several nucleotide triplets encode the same amino acid. The abundance of tRNAs that recognize particular codons differ between organisms and this can have large effects on the expression of protein products [39] . The genes of papillomaviruses use codons that are not commonly used by mammalian cells and substituting them with codons preferentially used by the mammalian genome results in increased translation of the genes, as described for L1 [40] , and their immunogenicity, as described for E7 [41] . These finding imply that HPV has evolved to exploit the redundancy in genetic code to control the expression levels of its gene products. This, combined with a variety of other transcriptional and translational control mechanisms that prevent expression of the L genes in the undifferentiated layers of the epithelium [42] , allows escape from detection by the immune system.
Sequence Similarity to Human Proteins
Molecular mimicry is defined as the process in which structural properties of an introduced molecule imitate or simulate molecules of the host. Either the linear amino acid sequences or the conformational fits of the molecules may be shared, even though their origins are as separate as, for example, a virus and a normal host self determinant [43] . An immune response against the determinant shared by the host and virus can evoke a tissue-specific immune response that is presumably capable of eliciting cell and tissue destruction. To maintain tissue and organ integrity, the host immune system must be able to distinguish between self and non-self molecules and be tolerant to self-molecules. Mimicking host-proteins and thereby taking advantage of the host's selftolerance toward important cellular proteins may be a mechanism by which HPV escapes functional antigenspecific immune recognition. Evidence for this comes from an analysis of the HPV16 E7 protein that has wide spread similarity to several human proteins involved in critical regulatory processes [44] . Two of the proteins that share common motifs with the HPV16 E7 protein are the xeroderma pigmentosum group G complementing protein (XPGC) and the retinoblastoma binding protein 1 (RBP-1). Thus, a cell-mediated response that targets the common motifs of these proteins would result in inhibition of excision repair [45, 46] or derangement of cell cycle regulation [47] , respectively. Since there is no evidence that human T-cells target the shared epitopes from these proteins, it may be that sharing of epitopes is one of the mechanisms that HPV has evolved to escape immune recognition.
Modulation of Antigen Presentation
It is well known that neutralizing antibodies may be an effective way to prevent infection and control spread of HPV. However, T-cells are important in controlling HPV infections and HPV-induced tumors. Evidence for this comes from studies on spontaneous regression of HPVinduced warts [48] , clinical data from immune-suppressed or immune-deficient patients [10, [49] [50] [51] [52] as well as models of HPV-induced tumors [53] [54] [55] [56] [57] . Thus, there is ample evidence that cell-mediated control is required for resolution of HPV infections and HPV-induced tumors [58] [59] [60] . T-cells recognize infected cells through interactions of their receptors with viral peptides bound to major histocompatibility (MHC) complexes on the surface of the infected cells. HPVmediated dysregulation of the antigen processing machinery would result in down-regulation of peptide-MHC complexes on the surface of infected cells and protect them from immune attack.
Evidence that HPV associated tumors exhibit loss of MHC class I is well-documented [61] [62] [63] [64] . Immunogenic peptides from both E7 [65] and E6 [66] proteins are not efficiently processed and presented by HPV+ tumor cells and this correlates with reduced expression of human leukocyte antigen (HLA) class I, proteasome subunits low molecular mass protein (LMP) 2 and 7, and the transporters of antigenic peptides (TAP) 1 and 2 in cervical carcinoma cell lines [66] . This tumor cell phenotype may be a result of natural selection as opposed to a direct result of viral gene functions to enable escape from the immune system. However, HPV-induced benign lesions of the larynx also exhibit reduced MHC class I expression as well as reduced TAP-1 expression [67, 68] . A variety of mechanisms that cause MHC class I dysregulation have been described in tumor cells including HLA class I allelic transcription but no protein; abnormal HLA class I allelic transcription; no HLA-B locus transcription; loss of heterozygosity; no interferon (IFN)-gamma-mediated up-regulation of HLA class I expression, and/or no IFN-gamma-mediated HLA class II induction [69] . More recent experiments have investigated the involvement of HPV proteins and the data implicate the involvement of E5 and E7 in the disruption of antigen presentation through some of these mechanisms as well as others described here.
The E7 protein of HPV is mostly found in the nucleus of infected cells [35] and regulation of transcription is one of the many functions of this protein [18, [70] [71] [72] [73] [74] . The E7 proteins of both HPV16 and HPV18 repress the promoter for MHC class I heavy chain expression [75] . HPV18 E7 also represses activity of a bidirectional promoter that regulates expression of the TAP1 and LMP2 genes, whereas HPV16 E7 does not. Expression of the low-risk HPV 6b E7 protein increases MHC class I heavy chain promoter activity, while repressing the TAP1/LMP2 promoter [75] . E7 from low-risk HPV6 and HPV11 co-precipitates as a complex with both TAP1 and calreticulin, and purified E7 from HPV 11 inhibits ATP-dependent transport, which results in poor presentation of viral antigens [76] . Thus, E7 regulates transcription of genes associated with antigen presentation and inhibits their function, which reduces viral peptides presented on the surface of infected cells and helps the virus to escape detection by cytotoxic T-cells (CTL). Some cervical cancer patients have detectable HPV16-E7 specific CTL [77, 78] . However, even after vaccination, E7-specific CTL activity is low [79] [80] [81] . Transplantation studies with E7 expressing keratinocytes combined with adoptive transfer of E7-specific CTL describe E7 to be peripherally tolerigenic [82] [83] [84] . Whether the E7-induced peripheral tolerance occurs due to poor antigen presentation by non-professional APC or due to anergy of high-avidity E7-specific CTL is an area of active investigation. It may be that poor antigen presentation due to down-regulation of antigen presentation machinery results in the induction of HPV-specific T cell anergy.
The HPV16 E5 protein possesses mitogenic activity that acts synergistically with epidermal growth factor (EGF) in human keratinocytes. It inhibits the degradation of the EGFR in endosomal compartments after ligand-stimulated endocytosis via interaction with the 16-kD pore-forming subunit of the vacuolar H(+)-ATPase (V-ATPase) and inhibits endosome acidification [85] . Similarly, it also interferes with the pH homeostasis of the Golgi complex [86] . Since stability of the MHC class I complex with peptide is pH dependent [87, 88] , HPV16 E5-mediated alkalinization of the Golgi complex and endosomes may lead to disruption of the exocytic and endocytic trafficking, including transport of the MHC class I complex [89] . Moreover, HPV16 E5 only down-regulates surface expression of HLA-A and HLA-B, which present viral peptides to MHC class I-restricted CTL, but not the natural killer (NK) cell inhibitory ligands HLA-C and HLA-E [89] . Though the exact mechanism of how E5 disrupts MHC class I presentation on the cell surface is not understood, the selective down-regulation of MHC class I may allow the virus to establish infection by avoiding both CTL and NK cells. In addition to disrupting the MHC class I pathway, HPV16 E5 has also been shown to interfere with MHC Class II antigen presentation, most likely via a similar mechanism. The invariant chain (Ii) is a chaperone protein whose sequential degradation within acidic endocytic compartments is required for loading of antigenic peptide onto MHC class II molecules. E5 has been shown to prevent the breakdown of Ii and block the formation of peptideloaded, mature MHC class II dimers, which correlates with diminished surface MHC class II expression [90] . This suggests that as well as interfering with CTL and NK cell recognition of infected cells, HPV may inhibit CD4+ T-cell recognition through down-regulation of MHC class II molecules and thereby evade the immune system.
Interference with IFN
Named for their ability to interfere with viral replication [91] , interferons are soluble factors that can limit both lytic and non-lytic viral infections as well as activate or attract cells of the immune system including neutrophils, macrophages, NK cells, and DC. They can be classified as type I (IFN-alpha/beta) or type II (IFN-gamma), based on sequence homology and the receptor used for signaling [92] . Type I IFN, produced by infected cells, have anti-viral, antiproliferative, anti-angiogenic and immune-stimulatory activities. They also act as a bridge between innate and adaptive immunity [93, 94] through the induction of IFNstimulated gene (ISG) transcription [91] . Binding of type I IFN to their receptor stimulates signal transduction via the formation of the ISG factor-3 (ISGF-3) transcription complex, which binds IFN-stimulated response element (ISRE) in the nucleus and results in the initiation of transcription. IFN-regulatory factors (IRF) are a family of transcription factors that mediate both virus and IFN signaling pathways, which are involved in anti-viral defense, immune response and cell growth regulation. They play an essential role in regulating the expression of type I IFN genes, ISG and other cytokines (reviewed in [95] ) via binding to the ISRE. The importance of the IFN pathway in viral immunity is demonstrated by the fact that many viruses have evolved mechanisms to disrupt it [96] .
Both in vitro and in vivo data suggest that HPV has also evolved mechanisms to avoid the effects of type I IFN. IFNalpha does not effectively inhibit transcription of E6/E7 RNA in several human cervical epithelial cell lines immortalized by recombinant HPV-16, -18, and -33 DNA, whereas IFN-gamma that is secreted by immune cells present in regressing HPV infections does [97] . Furthermore, premalignant lesions from patients non-responsive to treatment with IFN-alpha have higher levels of E7 mRNA as compared with patients that respond to treatment, suggesting that HPV E7 may inhibit the ISRE [98] . The mechanism by which E7 inhibits IFN-alpha-mediated signal transduction is via binding to the p48/IRF-9 and preventing its translocation to the nucleus, thereby inhibiting the formation of the ISGF-3 transcription complex that binds ISRE in the nucleus [99, 100] . Another mechanism by which E7 interferes with the IFN-mediated signaling is by physically associating with IRF-1 and inhibiting IRF-1 mediated activation of the IFNbeta promoter by recruiting histone deacetylase to the promoter, thereby preventing transcription [101] . In vivo expression of HPV18 E7 results in the reduced expression of IRF-1 target genes such as TAP-1, IFN-beta and monocyte chemo-attractant protein-1 (MCP-1), via inhibition of the trans-activation function of IRF-1 [102] . Conditional expression of E7 also inhibits NFkappaB DNA binding activity and can therefore dysregulate NFkappaB-induced gene expression [103] .
The E6 protein of HPV also appears to target the IFN pathway. E6 binds to IRF-3, a factor that is produced constitutively in most cell types and present in the cytoplasm in an inactive form [104] . HPV16 E6 binding to IRF-3 inhibits its trans-activation function, thereby preventing transcription of IFN-beta mRNA [105] . E6 also binds to Tyk2. This prevents Tyk2 binding to the cytoplasmic portion of IFN-alpha receptor 1, and inhibits phosphorylation of Tyk2, STAT-1 and STAT-2, thereby impairing Jak-STAT activation and thus interfering specifically with IFN-alpha mediated signaling [106] . More recently, cDNA micro-array analysis of gene expression showed that HPV16 E6 altered expression of three groups of genes: IFN-responsive genes, NFkappaB-stimulated genes and cell cycle regulation genes; an effect that cumulated with E7 co-expression [107] . E6 decreased expression of IFNalpha and -beta, down-regulated nuclear STAT-1 protein, and decreased binding of STAT-1 to the ISRE [107] . Thus, like E7, E6 directly alters expression of genes that enable host resistance to infection and immune function.
Inhibition of Cytokines and Chemo-Attractants
One of the earliest responses to infection is the release of proteins that mediate the immune response. Cytokines, chemokines, adhesion molecules and proteases are all molecules that direct the migration of cells of the immune system and elicit local infiltration of inflammatory and immune cells. Altered expression of these proteins would hinder and may even inhibit the immune response that would clear infection. Interfering with cytokine patterns would allow HPV to evade the immune response and in addition to the well-documented effects on cell cycle regulation, the E6 and E7 proteins of HPV have been shown to inhibit the production of immune mediators.
Identified as one of the first chemokines [108, 109] , MCP-1 attracts a variety of cell types including monocytes, memory T cells and NK cells [110] , and is therefore particularly relevant in the clearance of viral infections. In the setting of HPV, MCP-1 expression is suppressed after infection [111] . The mechanism by which HPV suppresses MCP-1 production is not known, but E6 and E7 from highrisk HPV have been shown to, individually and together, suppress MCP-1 expression in primary epithelial cells derived from the female genital tract [112] . Interleukin-8 (IL-8) is another chemokine and is produced by a wide variety of cell types, including almost all of the nucleated cells within the body. However, among these cells, monocytes and macrophages typically represent the principal cellular source [113] . Initially identified as a chemo-attractant for neutrophils, IL-8 is now known to function as a potent activator and chemo-attractant for neutrophils, basophils and T cells [113, 114] . In the setting of HPV infections, expression of IL-8 is down-regulated when E6 and E7 are expressed. Together, E6 and E7 inhibited transcription of the IL-8 promoter to a greater extent than either alone [115] . This suggests that suppressing chemokine expression and thereby inhibiting the infiltration and activation of T cells and NK cells could be a mechanism used by HPV to avoid an immune attack.
Interleukin-18 (IL-18) is a pro-inflammatory cytokine defined by its ability to stimulate the expression of genes associated with inflammation. Initially identified as an endotoxin-induced serum factor that stimulated IFN-gamma production [116] , IL-18 is now recognized as an important regulator of innate and acquired immune responses and the knowledge of its effector functions is rapidly expanding (reviewed in [117] ). Since it helps to prime CD8+ T-cells crucial for viral clearance (demonstrated by the observation that IL-18 is protective in viral infections [118] and viral clearance is impaired in IL-18 deficient mice [119] ), downmodulation of IL-18-induced immune responses by HPV proteins may contribute to viral pathogenesis and eventual carcinogenesis by allowing the virus to escape detection. Transfection experiments to determine whether the oncoproteins of HPV could modulate IL-18 expression showed that HPV16 E6, and not E7, down-regulated IL-18 expression via a p53 independent pathway [120] . Since E6 did not inhibit the activities of IL-18 promoters and E6 binds IL-18, IL-18 might be degraded by E6 via the ubiquitin pathway or any other pathways, and this prevents IL-18 induction of IFN-gamma [120] . Alternatively, HPV16 E6 and E7 proteins competitively bind to the IL-18 receptor and thus may inhibit IL-18-induced IFN-gamma production locally in HPV lesions through inhibition of IL-18 binding to its alpha-chain receptor [121] . IL-18 has been shown to synergistically enhance the production of IFN-gamma in human NK cells along with IFN-alpha [122] and IFNgamma contributes to the cytolytic functions of NK cells [123] . Thus, though it remains to be shown, the downregulation of IL-18 by HPV16 E6 may impede NK cell activity.
Skewing Cytokine Profiles
CD4+ helper T cells are functionally polarized into two subsets that produce different patterns of cytokines: Th1 cells produce mainly IL-2 and IFN-gamma, whereas Th2 cells produce IL-4, IL-5, IL-6, IL-10 and IL-13. Th1 cells are mostly involved in cell-mediated reactions, while the Th2 cytokines are commonly found in association with strong antibody and allergic responses. Moreover, the characteristic cytokine products of Th1 and Th2 cells are inhibitory for the differentiation and effector function of the opposite subset [124] . Skewing of the cytokine profile would lead to an inappropriate immune response, which may have immunosuppressive effects that result in the inability of the host to clear infection. CTL responses are essential in controlling HPV infections and since Th1 responses favor the development of CTL, it is possible that HPV has evolved mechanisms to disfavor the induction of Th1 responses. Most studies have focused on the cytokine profiles in HPV-associated cancers and show that the presence of Th2 cytokines correlates with progression to invasive tumors [125] [126] [127] [128] . Furthermore, tumor-infiltrating lymphocytes in cervical cancers are predominantly of a Th2/Tc2 polarity [129] and the draining nodes appear to have an increased proportion of T regulatory cells [130] . However, this may be brought on by the tumor rather than an immune evasion mechanism used by HPV. A more recent study compared cytokine profiles in the cervical secretions of HPV DNA(+) and HPV DNA(-) cytologically normal cervices described elevated levels of IL-10 in HPV DNA(+) samples [131] . Elevated IL-10 in early cervical lesions may inhibit immune responses against HPV infection. This data suggests that skewing of the cytokine profile to one that is immunosuppressive may be HPV induced and occur prior to the development of cancerous lesions, though the mechanism by which this occurs is yet to be elucidated.
Modulation of Adherence Molecules
Dendritic cells are antigen-presenting cells (APC) that play an important role in the capture and presentation of antigens to stimulate T cells [132] . The confinement of HPV infection to the epithelia puts the epithelial dendritic cells, the Langerhans cells (LC), in charge of the induction of T cell-dependent immunity. As HPV-infected keratinocytes cannot reach the regional lymphoid organs, priming of antiviral T-cells depends on LC, which continuously monitor the epidermal microenvironment for infection and damage. Clinical observations show that the number of LC is significantly reduced at sites of HPV infection [133, 134] . Adhesion molecules, such as E-cadherin, are necessary to mediate contact between LC and keratinocytes [135, 136] and the expression of HPV16 E6 alon79s of cell surface Ecadherin, thereby interfering with E-cadherin-mediated adhesion [137] . How this happens has yet to be described. Normal LC also express adhesion molecules like E-cadherin [135] , ICAM-1, VCAM-1 [138] , LFA-3 [139] etc but there is no expression of any adhesion or co-stimulation molecule by epithelial LC in pre-malignant or malignant cervical biopsy specimens [126] . HPV can infect LC [140] [141] [142] [143] , but whether any HPV protein regulates adhesion molecule expression in LC is unknown. Nevertheless, the lack of adhesion between LC and epithelia may be due to lack of Ecadherin expression on epithelial cells and may be one explanation for a reduction in LC density in the local milieu at sites of infection. In this way, E6-mediated downregulation of E-cadherin expression in keratinocytes may indirectly limit presentation of viral antigens by LC to the immune system, consequently preventing the initiation of a cell-mediated immune response and promoting survival of the virus.
Modulation of Intracellular Signaling
Studies on HPV and the development of vaccine strategies have been hindered by the difficulty in producing virus particles in vitro. In an effort to overcome this difficulty, HPV virus-like particles (VLP) that are composed of the self-assembling L1 capsid protein have been used [14, 30] . Since they can be recognized by human anti-sera from infected individuals [144] , indicating that their antigenic determinants are similar to those of native HPV, HPV-VLP currently serve as a model to study the interaction of HPV with cells of the immune system. Investigations on the interactions of HPV16-VLP with dendritic cell subsets have shown that LC do not get activated when incubated with VLP and do not initiate epitope-specific immune responses against L1-derived antigens [145] . Contrarily, myeloid dendritic cells are activated by VLP and stimulate HPV-specific T cells [146] . Furthermore, LC can present HPV-derived peptides, but do so in the absence of costimulation, thereby becoming immune-suppressive [147] . Differing intra-cellular signaling cascades are initiated in DC and LC upon uptake of HPV-VLP. While the mitogenactivated protein kinase (MAPK) pathway is activated in DC, it is inactivated in LC when they are stimulated with HPV-VLP. However, the phosphoinositide 3-kinase (PI3-K) is activated in LC, leading to a signaling cascade that results in the inactivation of Akt, which can be reversed by inhibiting PI3-K. Blocking of PI3-K also reverses the phenotype of HPV-VLP stimulated LC from immunesuppressive to immune-stimulatory, indicating that HPV inhibits LC from inducing an immune response by activating PI3-K while down-regulating MAPK upon infection [148] .
Inhibition of APC Migration
Although LC are maintained in the epidermal microenvironment, the precursors are recruited under inflammatory conditions, when local LC are lost [149] . This recruitment is dependent upon cytokines and chemokines secreted by epidermal cells, among which macrophage inflammatory protein-3alpha (MIP-3alpha) is the most potent chemotactic agent for LC precursors [150] . MIP-3alpha is produced by a variety of tissues [151] including epidermal keratinocytes, but primarily in areas of inflamed epithelium [152] . Cells expressing the receptor for MIP-3alpha (called CCR6), such as memory T cells [153] and LC precursors [154] , migrate in response to MIP-3alpha expression. Cells expressing E6 and E7 proteins from both high and low risk HPV types produce less MIP-3alpha, which results in reduced migration of LC precursors [155] . A lack of MIP-3alpha expression could negatively impact the numbers of LC at the sites of inflammation, which are significantly reduced in areas of HPV persistence. Thus, in addition to down-regulation of adherence molecules in the epidermis, interference with the expression of chemokines that attract APC could be a mechanism by which HPV could persist undetected.
Prevention of Apoptosis
Apoptosis, or programmed cell death, is initiated by specific biological signals and two main apoptotic routes have been identified [156, 157] . In the extrinsic death receptor pathway, receptors are activated specifically by their cognate ligands, such as Fas-Fas ligand (FasL) interaction. The intrinsic mitochondrial pathway is used in response to many nonspecific stimuli, e.g. DNA damage, radiation, and osmotic stress [158] , resulting in cytochrome c release from the mitochondrial inter-membrane space. Both pathways converge at the level of caspase-3 activation. Inhibition of apoptosis of HPV-infected cells could be a mechanism to promote survival of the virus. Furthermore, if the expression of death receptor ligands were up-regulated on the surface of infected cells, they may induce apoptosis of activated T-cells that mount an immune response. The E6 protein of HPV-16 and other HPV binds cellular p53 and the binding correlates with the in vivo clinical behavior and the in vitro transforming activity of these different papillomaviruses [159] . E6 binding to p53 stimulates the degradation of p53 in an ATP-dependent manner that involves the ubiquitindependent protease system. Thus, E6 prevents intrinsic, p53-dependent apoptosis of infected cells. E5 suppresses FasL mediated-apoptosis and this is associated with a two-fold reduction in Fas expression. Although E5 also suppresses tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) mediated-apoptosis, no such down-regulation was observed [160] . This was further investigated using raft cultures because it allows analysis of apoptosis under more tissue-like conditions by mimicking the stratified organization of a normal surface epithelium and similar results were obtained [160] . Thus, inhibition of apoptosis may be a primary function of the HPV-16 E5 protein needed to prevent apoptosis at early stages of viral infection and promote its survival. Whether FasL expression on infected cells is up-regulated by any of the HPV proteins has yet to be determined.
CONCLUDING REMARKS
During initial infection, HPV is present as an episome. In advanced lesions, it is integrated into the host genome, which leads to the inactivation of E2, an early protein that regulates expression of E6 and E7. Since E6 and E7 are the major transforming proteins of HPV, deregulated expression of these proteins allows for the accumulation of a variety of genetic changes that facilitate tumor cell survival and immune escape, over the decades required to develop malignancy. Thus, in order to survive, the transformed carcinogenic cells must also evade immune-surveillance. Over and above taking advantage of the escape mechanisms used by HPV, tumor cells have evolved additional mechanisms to evade the immune system such as selection for assembly-deficient L1 mutants that do not activate innate or adaptive immune responses initiated by DC [161] , secretion of immune-suppressive proteases [162, 163] , production of transforming growth factor beta (TGF-beta) [164] , global deactivation of T cells at tumor sites [165] , and down-regulation of CD25 on activated tumor infiltrating lymphocytes [166] . Since HLA molecules present peptides for immune-recognition of infected cells, the HLA type may also influence susceptibility to the development of HPVrelated cancers [167] . If some HLA types are unable to bind HPV peptides with high affinity, it may impact the ability of the individual to clear the virus, allowing the infection to persist. There is epidemiological evidence to suggest that certain HLA types carry a higher risk for the development of HPV-related cancers [168] .
Though HPV is a relatively simple virus with few genes, in order to survive, it has evolved intricate ways to escape the host immune system. The species-specificity and difficulty in in vitro propagation have made HPV a challenging virus to study. Many details of how the virus escapes host immunity are yet to be understood, particularly during natural infections. Regardless, it seems probable that evolution has shaped a pathogen that propagates by a combination of stealth and interference with both the innate and adaptive components of the immune system. Despite the many mechanisms by which HPV can evade the host immune system, the majority of immune-competent individuals infected with the virus are eventually able to clear infections. Therefore, although persistent infection is the greatest risk factor for the development of HPV-related cancers, progression to cancer requires more than just HPV infection and persistence. Future investigations of the host-HPV relationship may provide a deeper understanding of the nature of HPV-resistance to host immunity as well as the development of HPV-induced cancers, which may in turn lead to better strategies to treat virus-induced cancers.
